A clinical study evaluating the psychometric properties of the experimental nine-item EQ Health and Wellbeing questionnaire, designated as the EQ-HWB-9 2022 version, has demonstrated generally satisfactory construct validity and preliminary evidence of responsiveness among patients diagnosed with gastric, pancreatic, and colorectal cancer.
The clinical investigation was conducted at a major tertiary hospital located in Shanghai, China, where researchers prospectively enrolled patients across three gastrointestinal oncology cohorts. The final analytical population comprised 502 total participants, specifically incorporating 164 patients with gastric cancer, 135 patients with pancreatic cancer, and 203 individuals undergoing treatment for colorectal cancer. Each participating patient completed the experimental EQ-HWB-9 along with established comparator instruments during two routine visits, while comprehensive clinical information was extracted directly from hospital medical records.
To evaluate convergent validity, the researchers examined how the experimental EQ-HWB-9 index score correlated with several widely recognized generic and cancer-specific instruments. Participants completed the generic EQ-5D-5L and SF-6Dv2 questionnaires during their visits. In addition, patients completed the FACT-G questionnaire, from which the preference-based FACT-8D utility score was extracted, and the EORTC QLQ-C30, from which the QLU-C10D index was derived, alongside single-item rating scales assessing global health status and overall quality of life.
The statistical analyses demonstrated moderate to strong positive correlations between the experimental EQ-HWB-9 index score and the comparative measures, with correlation coefficients ranging from 0.46 to 0.80 across the three cancer types. These substantial associations with the EQ-5D-5L, SF-6Dv2, FACT-8D, and QLU-C10D, as well as the global rating scales, confirmed convergent validity by demonstrating that the experimental nine-item tool effectively aligns with validated assessments of patient wellbeing and functional capacity.
Known-groups validity was also evaluated to determine how effectively the questionnaire distinguished between patient subsets characterized by differing physical and economic burdens. Across all three cancer types, the EQ-HWB-9 index score successfully differentiated patients according to their Eastern Cooperative Oncology Group performance status, generating large Cohen’s d effect sizes that ranged from 0.94 to 1.49. In addition, the measure demonstrated significant discriminative validity regarding patient-reported financial burden, producing Cohen’s d values between 0.38 and 0.49.
However, the instrument exhibited clear limitations when differentiating clinical disease stages. While known-groups validity for cancer stage was successfully demonstrated in both gastric and pancreatic cancer cohorts, displaying Cohen’s d effect sizes from 0.29 to 0.49, the experimental EQ-HWB-9 failed to discriminate cancer stage among patients with colorectal cancer.
Longitudinal responsiveness across routine clinical visits was analyzed through standardized response mean values, referred to as SRM metrics, calculated separately for anchor-defined improved and deteriorated patient groups. For patients categorized as improved, SRM values revealed noticeably higher responsiveness in pancreatic cancer than in gastric and colorectal cancer patients. Conversely, among anchor-defined deteriorated patients, SRM values were similar across all three cancers, showing that the questionnaire detected health deterioration with consistent sensitivity across the cohorts.
In their conclusions, the study authors affirmed that the experimental EQ-HWB-9 2022 version demonstrated generally satisfactory construct validity alongside preliminary responsiveness across these gastrointestinal malignancies.
Subject of Research: Psychometric evaluation of the experimental EQ-HWB-9 questionnaire in gastrointestinal cancer patients
Article Title: Construct validity and responsiveness of the EQ-HWB-9 in patients with gastric, pancreatic, and colorectal cancer
Article References: Zhang, X., Cheng, L. J., Zhou, T., Luo, N., & Ji, M. (2026). Construct validity and responsiveness of the EQ-HWB-9 in patients with gastric, pancreatic, and colorectal cancer. Health and Quality of Life Outcomes. https://doi.org/10.1186/s12955-026-02620-x
Image Credits: AI Generated
DOI: 10.1186/s12955-026-02620-x
Keywords: EQ-HWB-9, EQ-5D-5L, SF-6Dv2, FACT-8D, QLU-C10D, FACT-G, EORTC QLQ-C30, gastric cancer, pancreatic cancer, colorectal cancer, construct validity, known-groups validity, convergent validity, responsiveness, standardized response mean, ECOG performance status, financial burden, psychometric evaluation
News Source: Ophelia Keating. (November 21, 2026). Experimental EQ-HWB-9 Shows Construct Validity Across Three Gastrointestinal Cancers. Scienmag.



